- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03037437
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Phase 2 study with two cohorts:
Cohort 1: As second-line treatment, we will add HCQ to SOR dose the patient was tolerating at the time of progression.
Cohort 2: SOR-naïve patients receive SOR 400 mg by PO twice daily on Cycle1 Day1 (C1D1). On Cycle 1 Day 15, HCQ 400 mg PO daily will be started. In clinical practice, dose reduction of SOR may be required. On C1D15 SOR maybe kept as starting dose or reduced for toxicity. On Cycle 2 Day 1 of toxicity of HCQ and SOR will be assessed.
Each cycle is 28 days.
Blood samples will be collected at Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 2 Day 1 to assess for biomarkers.
Disease evaluation every 2 cycles.
Dose reductions due to adverse events are allowed for both sorafenib per standard of care and/or HCQ for grade 3 or more adverse event was related to study medication. Dose reductions are also permitted based on investigator clinical decision.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Epp Goodwin
- Phone Number: 210-450-5798
- Email: ctrcreferral@uthscsa.edu
Study Contact Backup
- Name: Sukeshi Patel Arora, MD
- Phone Number: 210-450-1015
- Email: aroras@uthscsa.edu
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Recruiting
- University of Texas Health Cancer Center
-
Contact:
- Epp Goodwin
- Phone Number: 210-450-5798
- Email: goodwine@uthscsa.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Cytologically or histologically confirmed advanced or metastatic HCC. If no histological diagnosis, patient must have imaging studies compatible with HCC.
- Age 18 years and above
- ECOG performance status of 0 or 1
- Not a candidate for curative treatments (i.e., resection, transplantation)
- Child-Pugh class A or B7 liver function
- Measurable disease as defined by RECIST 1.1
- Patients who received prior local therapy (e.g., TACE) are eligible.
- Documented virology status of hepatitis, as confirmed by screening HBsAg, anti-HBc, and/or anti-HCV
- Life expectancy> 3 months
- For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception. For men: agreement to use a barrier method of contraception during the treatment period
- Hematologic, Biochemical, and Organ Function within 7 days prior to Cycle 1 Day 1: Granulocyte count > 1500/mm3, Platelet count > 75,000/ mm3, Hemoglobin > 8 g/dL; Total bilirubin < 2.0; Albumin > 2.8g/dl; AST (SGOT) and ALT (SGPT) < 5 x ULN; Serum creatinine< 1.5 x ULN
- Cohort 1 (with sorafenib): No previous systemic therapy including sorafenib or chemotherapy treatment. Previous TACE and local treatments are permitted.
- Cohort 2 (on progression of sorafenib): Patients who have received prior sorafenib therapy for at least 4 weeks and has confirmation of disease progression on CT/MRI. Prior surgery or local therapy within 4 weeks prior to Cycle 1 Day 1, with the exception of palliative radiation therapy to the bone
Exclusion Criteria:
- Patients receiving prior therapy with HCQ.
- Patients with uncontrolled brain metastases. Patients with brain metastases must be asymptomatic and off corticosteroids for at least one week.
- Due to risk of disease exacerbation, patients with psoriasis are ineligible unless the disease is well controlled, and they are under the care of a specialist for the disorder who agrees to monitor the patient for exacerbations.
- Patients with previously documented macular degeneration or or untreated diabetic retinopathy (stable retinopathy is allowed).
- Patients may not be receiving any other investigational agents.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ.
- Patients requiring the use of enzyme-inducing anti-epileptic medication (phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine) are not eligible for entry into the study.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- QTc > 500 milliseconds (ms) at baseline.
- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease. Patients with NG-tube, J-tube, or G-tube will not be allowed to participate.
- Pregnant women are excluded from this study because sorafenib has the potential for teratogenic or abortifacient effects. For this reason, women of childbearing potential and men must also agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation.
- Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sorafenib, breastfeeding should be discontinued.
- Informed Consent - No study specific procedures will be performed without a written and signed informed consent document. Patients who do not demonstrate the ability to understand or the willingness to sign the written informed consent document will be excluded from study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: No prior systemic treatment
Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
In clinical practice, dose reduction of SOR is often required.
Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started.
C2D1 of each cohort, toxicity of HCQ will be assessed.
Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
|
Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
Other Names:
400mg by mouth daily
Other Names:
|
Experimental: Progress on sorafenib
As second-line treatment, we will add hydroxychloroquine (HCQ) to sorafenib (SOR) dose the patient was tolerating at the time of progression.
|
Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
Other Names:
400mg by mouth daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to tumor progression evaluated via tumor imaging
Time Frame: Through study completion, an average of 1 year
|
Computerized axial tomography (CAT) Scan or Magnetic resonance imaging (MRI) will be done at Screening, then every other cycle and evaluated using RECIST version 1.1
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sukeshi Patel Arora, MD, Cancer Therapy & Research Center University of Texas Health Science Center San Antonio
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Sorafenib
- Hydroxychloroquine
Other Study ID Numbers
- CTMS 16-0076
- HSC20160515H (Other Identifier: University of Texas Health Science Center- San Antonio)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Cancer
-
Ethicon, Inc.CompletedCarcinoma, Hepatocellular | Hepatocellular Carcinoma | Hepatocellular Cancer | Cancer, HepatocellularKorea, Republic of
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Asan Medical CenterSeoul National University Hospital; Hanyang University; Soon Chun Hyang UniversityRecruitingHepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IVKorea, Republic of
-
Allison O'Neill, MDRecruitingLiver Cancer | Fibrolamellar Carcinoma | Hepatocellular Carcinoma, Childhood | Liver Cancer, PediatricUnited States
-
Medical College of WisconsinWithdrawnHepatocellular Carcinoma | Liver Cancer | Hepatoma | Hepatocellular CancerUnited States
-
Daiichi Sankyo, Inc.TerminatedAdvanced Solid Tumors | Hepatocellular Cancer (HCC)United Kingdom
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingStage III Hepatocellular Cancer (CNLC Staging)China
-
Henan Cancer HospitalNot yet recruiting
Clinical Trials on Sorafenib (SOR)
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IV Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB... and other conditionsUnited States
-
BayerAmgenCompleted
-
Ohio State University Comprehensive Cancer CenterBayerTerminated
-
Technical University of MunichCompleted
-
Ottawa Hospital Research InstituteBayerCompletedMetastatic Colorectal CancerCanada
-
Yiviva Inc.RecruitingAdvanced Hepatocellular CarcinomaUnited States, Taiwan, China, Hong Kong
-
National Cancer Institute (NCI)CompletedNon-Small-Cell Lung CarcinomaUnited States
-
British Columbia Cancer AgencyWithdrawnLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)Canada
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Accelerated Community Oncology Research NetworkBayerTerminatedRenal Cell CarcinomaUnited States